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Paclitaxel is an important anticancer agent widely applied in the
treatment of breast, ovarian and lung cancer and AIDS-related
Kaposi’s sarcoma (Huizing et al, 1995a; Rowinsky and
Donehower, 1995). The drug is marketed as an intravenous (i.v.)
formulation consisting of 6 mg ml–1 paclitaxel dissolved in
Cremophor EL:ethanol 1:1 v/v. Many different dosages and time
schedules have been tested and further optimization of the clin-
ical application is currently pursued. Recently, we reported about
the oral route for administering paclitaxel to patients using the i.v.
formulation as a drinking solution diluted with water (Meerum
Terwogt et al, 1998, 1999). This work was based on preclinical
studies highlighting the important role of P-glycoprotein (P-gp)
in the oral bioavailability of paclitaxel (Sparreboom et al, 1997;
Van Asperen et al, 1997). P-gp in the gut builds a barrier to many
substrate xenotoxins and drugs, including paclitaxel. In patients,
administration of 60 mg m–2 paclitaxel with 15 mg kg–1 cyclo-
sporin A(CsA), a competitive inhibitor of both P-gp and
cytochrome P450 3A4, significantly increased the oral bioavail-
ability of paclitaxel by at least 7-fold and plasma concentrations
rose from negligible to potentially therapeutic levels (Meerum
Terwogt et al, 1998, 1999). To further enhance the systemic expo-
sure to paclitaxel we performed a dose-escalation study of oral
paclitaxel in combination with CsA (Malingré et al, 2000a).
Although dose-escalation of oral paclitaxel from 60 to 300 mg
m–2 resulted in a significantly higher systemic exposure to pacli-
taxel, this increase was moderate and not proportional with dose.
Similar results have been obtained by Rowinsky and co-workers
(Britten et al, 2000). A mass balance study, which was performed
in patients receiving the highest dose level (300 mg m–2),
revealed that a high fraction of the dose was recovered in the
faeces as unchanged drug suggesting incomplete absorption
(Malingré et al, 2000b). Moreover, high amounts of the co-
solvent Cremophor EL were also recovered in faeces and the
fractions of the dose of Cremophor EL and paclitaxel excreted in
faeces were significantly correlated (Malingré et al, 2000b). We,
therefore hypothesized that Cremophor EL limits the absorption
of paclitaxel by entrapment of the drug in the gastro-intestinal tract. 
This hypothesis was recently substantiated in preclinical
models using mdr1ab P-gp knock-out mice (Bardelmeijer et al,
2000). Cremophor EL given at dosages relevant to cancer
patients resulted in considerably decreased paclitaxel plasma
levels and substantially increased faecal excretion of unchanged
paclitaxel. Based on these preclinical results, we initiated this
clinical study in which each patient received 60 mg m–2 of oral
paclitaxel, in combination with 15 mg kg–1 of CsA, formulated
in Cremophor EL (5 ml m–2 or 15 ml m–2) at one occasion and
polysorbate 80 at the other with pharmacokinetic monitoring at
both occasions. 
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Summary The purpose of this study was to investigate the effect of the co-solvents Cremophor EL and polysorbate 80 on the absorption of orally
administered paclitaxel. 6 patients received in a randomized setting, one week apart oral paclitaxel 60 mg m–2 dissolved in polysorbate 80 or
Cremophor EL. For 3 patients the amount of Cremophor EL was 5 ml m–2, for the other three 15 ml m–2. Prior to paclitaxel administration patients
received 15 mg kg–1 oral cyclosporin A to enhance the oral absorption of the drug. Paclitaxel formulated in polysorbate 80 resulted in a significant
increase in the maximal concentration (Cmax) and area under the concentration–time curve (AUC) of paclitaxel in comparison with the Cremophor
EL formulations (P = 0.046 for both parameters). When formulated in Cremophor EL 15 ml m–2, paclitaxel Cmax and AUC values were 0.10 ± 0.06
µ M and 1.29 ± 0.99 µ M h–1, respectively, whereas these values were 0.31 ± 0.06 µ M and 2.61 ± 1.54 µ M h–1, respectively, when formulated in
polysorbate 80. Faecal data revealed a decrease in excretion of unchanged paclitaxel for the polysorbate 80 formulation compared to the
Cremophor EL formulations. The amount of paclitaxel excreted in faeces was significantly correlated with the amount of Cremophor EL excreted
in faeces (P = 0.019). When formulated in Cremophor EL 15 ml m–2, paclitaxel excretion in faeces was 38.8 ± 13.0% of the administered dose,
whereas this value was 18.3 ±15.5% for the polysorbate 80 formulation. The results show that the co-solvent Cremophor EL is an important
factor limiting the absorption of orally administered paclitaxel from the intestinal lumen. They highlight the need for designing a better drug
formulation in order to increase the usefulness of the oral route of paclitaxel © 2001 Cancer Research Campaign http://www.bjcancer.com 
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PATIENTS AND METHODS 
Patient population 
Patients with a histologically confirmed cancer refractory to
current therapies were eligible for the study. Previous radio-
therapy or chemotherapy was allowed, provided that the last
treatment was at least 4 weeks prior to study entry and any
resulting toxicities were resolved. Eligibility criteria included
acceptable bone marrow (white blood cells > 3.0 × 109 l–1;
platelets > 100 × 109 l–1), liver function (serum bilirubin ≤ 25
µ mol l–1; serum albumin ≥ 25 g l–1, renal function (serum creati-
nine  ≤ 160 µ mol l–1 or clearance ≥ 50 ml min–1) and a World
Health Organization (WHO) performance status ≤ 2. Patients
were not eligible if they suffered from uncontrolled infectious
disease, neurologic disease, bowel obstruction or symptomatic
brain metastases. Other exclusion criteria were concomitant use
of known P-gp inhibitors and chronic use of H2-receptor antago-
nists or proton pump inhibitors. The study protocol was
approved by the Medical Ethics Committee of the Institute and
all patients gave written informed consent. 
Study design 
6 patients received at 2 occasions, which were one week apart and
randomized, oral paclitaxel at a dose of 60 mg m–2 formulated in
Cremophor EL/ethanol and the same oral paclitaxel dose formu-
lated in polysorbate 80/ethanol. 2 cohorts of each 3 patients were
made, one of which received Cremophor EL 5 ml m–2 in the oral
paclitaxel formulation and the other Cremophor EL 15 ml m–2.
The polysorbate 80 formulation was the same between the 2
cohorts. Prior to oral paclitaxel intake patients received 15 mg kg–1
oral CsA. 
For the oral paclitaxel formulation with Cremophor EL (5 and
15 ml m–2), the standard i.v. formulation of paclitaxel was used
(Taxol®; 6 mg ml–1 paclitaxel in Cremophor EL: ethanol 1:1 v/v). 3
of the 6 patients received additional Cremophor EL (BASF,
Brussels, Belgium) of 10 ml m–2 to this formulation. The polysor-
bate 80 formulation was made similar to the i.v. Cremophor EL
formulation of paclitaxel with replacement of Cremophor EL by
polysorbate 80 (6 mg ml–1 paclitaxel in polysorbate 80:ethanol 1:1
v/v). To all formulations 25 ml of water was added to decrease
viscosity. Paclitaxel was retrieved from Hauser, Inc (Boulder,
USA), polysorbate 80 from Kolb (Hedingen, Switzerland). CsA
was administered as capsules (Neoral® Novartis, Basel,
Switzerland; base: corn oil, polyoxyl 40 hydrogenated castor oil)
30 minutes prior to oral intake of paclitaxel. 
An oral paclitaxel dose of 60 mg m–2 was chosen for safety
reasons. As we expected that the oral bioavailability of paclitaxel
formulated in polysorbate 80 would approach the bioavailability
of orally administered docetaxel, i.e. 90% (Malingré et al, 2001), a
dose of 60 mg m–2 oral paclitaxel administered within a time
period of 2 weeks was considered to be therapeutic and safe. To
prevent nausea and vomiting patients received 1 mg oral
granisetron (Kytril®) approximately 2 hours prior to oral paclitaxel
administration. In addition, patients received a light standard
breakfast (2 crackers and a cup of tea) at least 2 hours prior to oral
drug administration. Intake of food was not allowed until 2 hours
following intake of paclitaxel. 
2 weeks after the second oral course of paclitaxel, patients
received i.v. paclitaxel (Taxol®) administered as a 3-hour infusion
at a dose of 175 mg m–2. If it was considered to be in their best
interest patients continued on a 3-weekly schedule of i.v. pacli-
taxel. At the i.v. occasions, patients were premedicated to prevent
hypersensitivity reactions with dexamethasone 20 mg orally 12
and 6 hours prior to, clemastine 2 mg i.v. 30 minutes prior to and
cimetidine 300 mg i.v. shortly prior to paclitaxel administration.
Oral doses were given without this premedication regimen as
previous studies of oral paclitaxel have revealed that the co-
solvent Cremophor EL, suspect of causing the hypersensitivity
reactions (Dye and Watkins, 1980), was not absorbed following
oral administration of paclitaxel (Meerum Terwogt et al, 1998,
1999; Malingré et al, 2000a). 
Sample collection 
Blood samples for pharmacokinetic analyses were collected
during the 2 oral courses. Samples were obtained in heparinized
tubes pre-dosing, at 15, 30, 45, 60, 75 and 90 minutes and 2, 3, 4,
7, 10, 24 and 30 hours after paclitaxel ingestion. For the analysis
of paclitaxel, blood samples were centrifuged, plasma was sepa-
rated and immediately stored at –20˚C until analysis. For CsA
analysis, 1 ml of whole blood was transferred, stored at 4˚C and
analysed within one week after treatment. Urine was collected
from 0–24 h and 24–30 h after paclitaxel administration. Samples
were stabilized with a mixture of 5% Cremophor EL/ethanol 1:1
v/v to prevent paclitaxel precipitation and these samples were
stored at –20˚C until analysis. The stools were collected in sepa-
rate portions up to 6 days after dosing. The stools collected up to
30 hours after dosing were immediately stored at –20˚C, the stools
collected from 30 hours up to 6 days after dosing were stored at the
patients home and were frozen at day 6 at –20˚C. After defrosting,
the faecal samples were homogenized in 10 parts of water, with a
maximum of 2000 ml, and aliquots of the suspension were stored
at –20˚C until analysis. 
Sample analysis 
Paclitaxel and metabolite concentrations in plasma, urine and
faeces were determined using validated high-performance liquid
chromatography (HPLC) assays (Huizing et al, 1995b, 1995c;
Sparreboom et al, 1995). All assays used 2′ -methylpaclitaxel as
the internal standard. Pretreatment of the plasma samples involved
solid phase extraction (SPE) on Cyano Bond Elut columns.
Pretreatment of urine samples involved liquid–liquid extraction
(LLE) with n-butylchloride. Faecal samples were pretreated by
LLE with diethyl ether followed by automated SPE using Cyano
Bond Elut columns. The lower limit of quantitation for paclitaxel
and metabolites was 10 ng ml for plasma, 25 ng ml for urine and
250 ng ml for faeces homogenates. CsA whole blood concentra-
tions were analysed using a specific fluorescence polarization
immunoassay (FPIA, Abbott Laboratories, Amstelveen, The
Netherlands) (Chan et al, 1992). The concentration of Cremophor
EL in faeces was measured using a validated HPLC assay
(Sparreboom et al, 1996) with minor modifications and correc-
tions for the presence of liberated free ricinoleic acid (Van
Tellingen et al, 1999a). 
Pharmacokinetic analysis 
Non-compartmental pharmacokinetic methods were applied to
process the results (Gibaldi and Perrier, 1982). The maximal drug1474 MM Malingré et al 
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concentration (Cmax) and time to maximal drug concentration
(Tmax) were obtained directly from the experimental data. The 
area under the concentration–time curve (AUC) was calculated 
by the trapezoidal rule up to the last measured time point 
(AUCt) with extrapolation to infinity using the terminal rate
constant k. The excretion of paclitaxel, metabolites and
Cremophor EL in faeces and urine was calculated relative to the
administered dose. Statistical analysis of the data was performed
using the non-parametric Wilcoxon matched-pairs signed-rank
test. The a priori level of significance was P = 0.05. 
RESULTS 
Formulation in polysorbate 80 resulted in significantly higher Cmax
and AUC values of paclitaxel in comparison with the Cremophor
EL formulations (n = 6; P = 0.046 for both parameters) (Figures 1,
2, Table 1). Compared to the 5 ml m–2 Cremophor EL formulation,
mean intrapatient differences in Cmax and AUC values were 1.5-
fold, whereas these differences were 3.9-, and 3.2-fold, respec-
tively with 15 ml m–2 Cremophor EL. Tmax values of paclitaxel
were significantly lower with the polysorbate 80 formulation
compared to the Cremophor EL formulations (n = 6; P = 0.046). 
Formulation of paclitaxel in polysorbate 80 also resulted in
significantly higher Cmax and AUC values of CsA when compared
to the Cremophor EL formulations (n = 6; P = 0.028 for both para-
meters) (Figure 3, Table 2). Compared to 5 ml m–2 Cremophor EL,
Cmax and AUC values of CsA were 1.4- and 1.3-fold higher,
whereas these differences were 1.5- and 1.4-fold, respectively
with 15 ml m–2 Cremophor EL. Tmax values of CsA were not signif-
icantly different between the 2 paclitaxel formulations. 
Excretion of unchanged paclitaxel in faeces was lower in the
case of paclitaxel being formulated in polysorbate 80 compared to
Cremophor EL (Figure 4, Table 3). However, these differences did
not reach statistical significance (n = 6; P = 0.115). Importantly, in
2 patients receiving the Cremophor EL formulation, faeces 
collection was incomplete, resulting in relative low amounts of
paclitaxel excreted in faeces. Excretion of the metabolite 6α -
hydroxypaclitaxel was significantly higher with the polysorbate 80
formulation (n = 6; P = 0.046). Excretion of the metabolites 3′
p-hydroxypaclitaxel and 6α , 3′ p-dihydroxypaclitaxel was not
different between the 2 formulations. The amount of Cremophor
EL excreted in faeces was 10.3 ± 4.9% of the administered dose for
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Figure 1 Pharmacokinetic parameters of oral paclitaxel formulated in
Cremophor EL (Crem EL) 5 ml m–2 (closed symbols) or 15 ml m–2 (open
symbols) and polysorbate 80 (PS 80) 
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Figure 2 Individual paclitaxel plasma concentration–time curves of a
patient receiving oral paclitaxel formulated in Cremophor EL (Crem EL) 5 ml
m–2 and polysorbate 80 (PS 80) 
Table 1 Pharmacokinetic parameters of oral paclitaxel (60mg m–2) formulated in polysorbate 80 (PS 80)
and Cremophor EL (Crem EL) 5 ml m–2 (cohort 1) or 15 ml m–2 (cohort 2). Data are presented as means ± SD 
cohort AUC (µ Mh –1)C max (µ M) Tmax (h) 
Crem EL PS 80 Crem EL PS 80 Crem EL PS 80 
1 1.25 1.66 0.19 0.27 3.3 1.5 
(0.52) (0.11) (0.06) (0.04) (0.5) (0.5) 
2 1.29 2.61 0.10 0.31 4.1 2.9 
(0.99) (1.54) (0.06) (0.06) (2.7) (2.1) 
Figure 3 Pharmacokinetic parameters of oral cyclosporin A (CsA)
administered just prior to oral paclitaxel formulated in Cremophor EL (Crem
E L )  5m lm –2 (closed symbols) or 15 ml m–2 (open symbols) and polysorbate
80 (PS 80) the 5 ml m–2 group and 20.9 ± 16.0% of the administered dose for
the 15 ml m–2 group. The total fraction of Cremophor EL excreted
in faeces was significantly correlated with the amount of paclitaxel
excreted in faeces (P = 0.019, r = 0.886) (n = 6) (Figure 5). 
Excretion of orally administered paclitaxel in urine was
minimal, as observed previously (Malingré et al, 2000a, 2000b).
Urinary excretion of paclitaxel was 2.4 ± 1.1% of the adminis-
tered dose for the polysorbate 80 formulation (n = 6), 2.1 ± 0.7%
of the administered dose for the 5 ml m–2 Cremophor EL formu-
lation (n = 3) and 2.6 ± 0.7% of the administered dose for the
15 ml m–2 Cremophor EL formulation (n = 2). Urine collection
of one patient was incomplete due to loss of urine during
collection. 
DISCUSSION 
The results of this study show that the presence of Cremophor EL
in the i.v. formulation of paclitaxel used orally reduces the absorp-
tion of paclitaxel from the gut. Formulation of paclitaxel in
polysorbate 80 resulted in a significant increase in the Cmax and
AUC values of paclitaxel. The excretion of unchanged paclitaxel
in faeces was substantially lower for the polysorbate 80 formula-
tion and indicates an improved oral uptake. At the same time,
excretion of the major paclitaxel metabolite 6α -hydroxypaclitaxel
was significantly increased, which is also indicative of increased
absorption of the drug. The relationship between reduction in
the absorption of paclitaxel and Cremophor EL was evident.
The amount of paclitaxel excreted in faeces was significantly
Absorption of oral paclitaxel limited by Cremophor EL 1475
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Table 2 Pharmacokinetic parameters of oral cyclosporin A (15 mg kg–1) administered just prior to oral paclitaxel (60 mg
m–2) formulated in polysorbate 80 (PS 80) and Cremophor EL (Crem EL) 5 ml m–2 (cohort 1) or 15 ml m–2 (cohort 2). Data
are presented as means ± SD 
Cohort AUC (mg l–1h) Cmax (mg l–1)T max (h) 
Crem EL PS 80 Crem EL PS 80 Crem EL PS 80 
1 22.9 27.9 2.79 3.54 2.5 2.0 
(6.5) (4.6) (1.34) (0.93) (1.7) (0.5) 
2 21.4 29.9 2.53 3.78 1.7 1.8 
(7.0) (11.1) (0.80) (1.65) (1.6) (1.6) 
Table 3 Faecal excretion of paclitaxel and the metabolites 6α -hydroxypaclitaxel (6α -HP), 3′ p-hydroxypaclitaxel (3′ p-HP) and 6α ,3′ p-dihydroxypaclitaxel
(6α ,3′ p-DHP) after oral paclitaxel administration (60 mg m–2) formulated in polysorbate 80 (PS 80) and Cremophor EL (Crem EL) 5 ml m–2 (cohort 1) or 15 ml
m–2 (cohort 2). Data are presented as means ± SD 
Cohort Paclitaxel (% of dose) 6α -HP (% of dose) 3′ p-HP (% of dose) 6α ,3′ p-DHP (% of dose) total recovery (% of dose) 
Crem EL PS 80 Crem EL PS 80 Crem EL PS 80 Crem EL PS 80 Crem EL PS 80 
1 25.9 24.4 22.5 31.4 2.3 2.5 4.3 6.8 55.0 65.1 
(2.5) (10.0) (4.8) (9.1) (1.4) (1.8) (2.9) (3.9) (7.0) (6.2) 
2 38.8 18.3 22.3 23.7 2.8 1.7 2.5 2.5 66.4 46.2 
(13.0) (15.5) (12.6) (13.7) (0.3) (0.5) (0.7) (0.7) (3.0) (2.8) 
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Figure 4 Faecal excretion of paclitaxel and the metabolites 6α -
hydroxypaclitaxel (6α -HP), 3′ p-hydroxypaclitaxel (3′ p-HP) and 6α ,3′ p-
dihydroxypaclitaxel (6α ,3′ p-DHP) after oral paclitaxel administration in
Cremophor EL (Crem EL) 5 ml m–2 (closed symbols) or 15 ml m–2 (open
symbols) and polysorbate 80 (PS 80) 
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Figure 5 Faecal excretion of paclitaxel versus the faecal excretion of
Cremophor EL after oral paclitaxel administration in Cremophor EL 5 ml m–2
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correlated with the amount of Cremophor EL excreted in faeces.
Interestingly, Cremophor EL of the paclitaxel formulation also
reduced the absorption of CsA. Significantly higher Cmax and AUC
values of CsA were observed when paclitaxel was formulated in
polysorbate 80 rather than in Cremophor EL. This result is in line
with those obtained in our previously performed dose-escalation
study of oral paclitaxel given together with a constant dose of CsA
(Malingré et al, 2000a). Apparently, absorption of orally adminis-
tered paclitaxel and CsA are influenced by Cremophor EL by the
same mechanism. 
The results of this clinical study are in good agreement with
our preclinical data (Bardelmeijer et al, 2000). In mdr1ab P-gp 
knock-out mice, receiving 10 mg kg–1 paclitaxel in the standard
formulation, only about 7% of the dose was excreted in faeces as
unchanged drug, suggesting almost complete absorption from the
gastro-intestinal tract. However, when the dose of Cremophor EL
was increased by 7-fold, faecal excretion of unchanged drug
increased to 35% of the dose. Moreover, the plasma Cmax and AUC
values of paclitaxel were 4- and 1.6-fold lower, respectively. For
reasons of availability our preclinical and clinical studies with oral
paclitaxel performed thus far have used the standard i.v. formula-
tion of paclitaxel. Cremophor EL, a mixture of polyoxyethylated
triglycerides, is an essential compound in this formulation used to
solubilize paclitaxel in aqueous dilutions by formation of micelles,
which include the drug molecules within their hydrophobic core.
After oral paclitaxel administration, Cremophor EL was assumed
to be degraded in the gastro-intestinal tract as paclitaxel and
Cremophor EL levels recovered in faeces of mdrla P-gp knock-out
mice were very low (Sparreboom et al, 1997; Bardelmeijer et al,
2000). However, in our clinical study of oral paclitaxel 300 mg
m–2, a substantial fraction of the dose of Cremophor EL, i.e. 32%,
was recovered in faeces together with 61% of the dose of pacli-
taxel, indicative for incomplete degradation of Cremophor EL and
poor uptake of paclitaxel (Malingré et al, 2000b). By use of an in
vitro assay we have shown that micelles are being formed in the
intestines of mice at Cremophor EL concentrations of 0.33% w/v
and higher (Bardelmeijer et al, 2000). With the addition of extra
Cremophor EL to mdrlab P-gp knock-out mice, the levels 
of Cremophor EL in the intestinal contents were approximately
10-fold higher. It could then be concluded that the mechanism of
interaction between paclitaxel and Cremophor EL rests on the
property of Cremophor EL to form micelles, which entrap pacli-
taxel thus reducing the availability of paclitaxel for uptake
(Bardelmeijer et al, 2000). In line with this hypothesis it is likely
that the oral bioavailability of CsA is similarly affected. 
The selection of polysorbate 80 as vehicle used to replace
Cremophor EL was based on the following considerations (1) the
very good oral bioavailability of docetaxel, a taxane drug formu-
lated in polysorbate 80/ethanol (Malingré et al, 2001) and (2) the
rapid degradation of polysorbate 80 by esterases in plasma (Van
Telligen et al, 1999b). Initially, we planned to formulate paclitaxel
in polysorbate 80 similar to docetaxel (Taxotere®) with 20 mg drug
per 0.5 ml polysorbate 80 and 1.5 ml ethanol 13% g g–1. However,
no clear solution of paclitaxel could be made. Therefore, it was
decided to formulate paclitaxel in polysorbate 80 similar to the i.v.
Cremophor EL formulation with 6 mg drug per 0.5 ml polysorbate
80 and 0.5 ml absolute ethanol. This formulation was clear and
appeared feasible. Paclitaxel formulated in polysorbate 80 resulted
in a mean paclitaxel excretion in faeces of 21%, which suggests
incomplete uptake of the drug from the gut. We previously deter-
mined that after i.v. administration of paclitaxel (175 mg m–2) only
9% of the drug was recovered as unchanged paclitaxel in faeces
(Malingré et al, 2000b). The incomplete uptake of oral paclitaxel
formulated in polysorbate 80 may be caused by the relatively high
amount of polysorbate 80, which may have, to a certain extent,
similar capabilities as Cremophor EL of forming micelles, espe-
cially at higher concentrations. We are currently investigating a
new formulation of oral paclitaxel with a different solvent, which
may shed more light on this issue. 
In conclusion, the results show that the co-solvent Cremophor
EL is an important factor limiting the absorption of orally
administered paclitaxel from the intestinal lumen, in particular at
the higher dose levels. Development of a better, non-Cremophor
EL-based drug formulation is needed in order to increase the
usefulness of the oral route of paclitaxel. 
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